NM_013382.7:c.1397G>A
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_013382.7(POMT2):c.1397G>A(p.Arg466Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000539 in 1,613,796 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 16/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R466W) has been classified as Uncertain significance.
Frequency
Consequence
NM_013382.7 missense
Scores
Clinical Significance
Conservation
Publications
- muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- myopathy caused by variation in POMT2Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2Inheritance: AR Classification: MODERATE Submitted by: Ambry Genetics
- autosomal recessive limb-girdle muscular dystrophy type 2NInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- congenital muscular dystrophy with cerebellar involvementInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- congenital muscular dystrophy with intellectual disabilityInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- muscle-eye-brain diseaseInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- muscular dystrophy-dystroglycanopathy, type AInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000158 AC: 24AN: 152102Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000636 AC: 16AN: 251490 AF XY: 0.0000441 show subpopulations
GnomAD4 exome AF: 0.0000431 AC: 63AN: 1461694Hom.: 0 Cov.: 31 AF XY: 0.0000358 AC XY: 26AN XY: 727160 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000158 AC: 24AN: 152102Hom.: 0 Cov.: 32 AF XY: 0.000148 AC XY: 11AN XY: 74290 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Uncertain:2
- -
In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2;C3150416:Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2;C3150418:Autosomal recessive limb-girdle muscular dystrophy type 2N Uncertain:1
This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 466 of the POMT2 protein (p.Arg466Gln). This variant is present in population databases (rs138266415, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with POMT2-related conditions. ClinVar contains an entry for this variant (Variation ID: 471387). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt POMT2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at